News

Public · Published

Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides

Arrowhead Pharmaceuticals said adults in England and Wales with Familial Chylomicronaemia Syndrome, a rare metabolic condition, can now get REDEMPLO (plozasiran) on the NHS to lower extremely high triglycerides, a type of fat in the blood, when diet and conventional therapies have not worked well enough.

Published:

Updated:

What happened

Arrowhead Pharmaceuticals said adults in England and Wales with Familial Chylomicronaemia Syndrome, a rare metabolic condition, can now get REDEMPLO (plozasiran) on the NHS to lower extremely high triglycerides, a type of fat in the blood, when diet and conventional therapies have not worked well enough.

Confirmed

Global impact / market context

This gives Arrowhead a funded NHS market in England and Wales for plozasiran, which means the company can earn revenue from a public health system. That revenue may help offset the costs of developing the drug and support future research spending.

Analyst inference

FCS is a rare condition, so the number of patients is small, but treated patients can generate steady revenue per person. NHS funding with a commercial arrangement, meaning a confidential pricing deal, reduces the risk that doctors cannot prescribe the drug because of cost.

Analyst inference

What to watch

  1. NICE recommended NHS funding for plozasiran in adults with genetically confirmed FCS when diet and conventional triglyceride-lowering therapies have not worked well enough. Confirmed
  2. Watch how quickly NHS doctors begin prescribing plozasiran, since adoption speed will determine how soon Arrowhead records revenue from England and Wales. Proposed
  3. Watch whether sales of plozasiran grow enough to cover Arrowhead's research and launch costs, because weak uptake would limit the cash the drug generates. Analyst inference

Evidence

  • Original source link unavailable